Colgate Palmolive Co: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Oct 25, 2024 and accepted by EDGAR at Oct 25, 2024, 08:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $5.03bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-01-01 to 2024-09-30 | $15.16bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-07-01 to 2024-09-30 | $1.96bn | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2024-01-01 to 2024-09-30 | $5.98bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-07-01 to 2024-09-30 | $3.07bn | us-gaap:GrossProfit |
| Gross profit | 9 months2024-01-01 to 2024-09-30 | $9.18bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2024-07-01 to 2024-09-30 | $1.98bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-01-01 to 2024-09-30 | $5.83bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | $1.06bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-30 | $3.21bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-07-01 to 2024-09-30 | $210.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-01-01 to 2024-09-30 | $693.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | $737.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | $2.15bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | $0.90 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-01-01 to 2024-09-30 | $2.61 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | $0.90 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | $2.62 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 822,500,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-01-01 to 2024-09-30 | 824,200,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | $2.84bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-01-01 to 2024-09-30 | $377.0m | us-gaap:PaymentsToAcquireProductiveAssets |
| Share repurchases | 9 months2024-01-01 to 2024-09-30 | $1.28bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-09-30 | $1.23bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $5.81bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $16.77bn | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $5.57bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $15.94bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-09-30 | $7.91bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-09-30 | $20.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-09-30 | $435.0m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2024-09-30 | 817,010,957 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000021665-24-000044. Last ingested by Listed: Nov 6, 2026, 16:45 ET. Listed shows no prices and gives no investment advice.